← Issue №14/ week of Oct 4, 2026/Esophagus/Reflux

Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat-Dose Administration for up to 14 Days.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Esophagus/Reflux rct · n=73 · Oct 1, 2026 · Aliment Pharm Ther · IF 6.7

Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat-Dose Administration for up to 14 Days.

Basic scienceproton pump inhibitorsbasic science
Clinical takeawayNo clinical action yet: Phase 1 study in healthy subjects, not patients with erosive oesophagitis.
What it foundLinaprazan glurate (LG) achieved pH >4 within 10 minutes at 75 mg b.d. and 60 minutes at 50 mg b.d., with HTR pH >4 >95% after 14 days.
ContextSupports LG as a rapid-acting PCAB with dose-dependent pH control, extending Phase 2 findings in erosive oesophagitis.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Larsson K … Unge P · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues